Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 15/20 | 0.40 |
| ▸ | PARP1 | P09874 | 15/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 14/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20914353 | 0.92 | HSD11B1 (0.44) | HDAC3CYP2C9HDAC1HDAC6TNKS | |
| SCHEMBL20914075 | 0.90 | SMN1; SMN2 (0.46) | HDAC3CYP2C9HDAC1HDAC6TNKS | |
| SCHEMBL20914007 | 0.89 | PLAT (0.43) | HDAC3CYP2C9HDAC1HDAC6TNKS | |
| SCHEMBL20914105 | 0.88 | PLAT (0.42) | HDAC3CYP2C9HDAC1HDAC6TNKS | |
| SCHEMBL20914101 | 0.88 | MAPT (0.40) | HDAC3CYP2C9HDAC1HDAC6TNKS | |
| SCHEMBL20914147 | 0.88 | PLAT (0.38) | HDAC3CYP2C9HDAC1HDAC6TNKS | |
| SCHEMBL20914226 | 0.88 | PLAT (0.47) | — | |
| SCHEMBL20914320 | 0.85 | HCRTR1 (0.41) | MEN1ALDH1A1POLBKMT2AL3MBTL1 | |
| SCHEMBL20913954 | 0.85 | PLAT (0.36) | HDAC3CYP2C9HDAC1HDAC6TNKS | |
| SCHEMBL20931237 | 0.85 | PLAT (0.36) | HDAC3CYP2C9HDAC1HDAC6TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | HDAC3 1789/4885CYP2C9 763/4885HDAC1 2057/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | HDAC3 1789/4885CYP2C9 763/4885HDAC1 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.